HIV Infections Clinical Trial
Official title:
Using Incentives to Improve Parolee Participation and Attendance in Community Tx
Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse
Programs (ISAP), in collaboration with Walden House and the California Department of
Corrections and Rehabilitation, is conducting a five-year study that will involve a
randomized test of the use of incentives with parolees in a community-based residential
substance abuse treatment program to increase treatment admission and treatment retention,
and thereby increase the likelihood of improved outcomes. Study participants will be
recruited from clients in a prison-based treatment program who have a referral to the Walden
House community program. The Admission Phase of the study assesses the effect of an
incentive (voucher) on enrolling in the Walden House program. The Attendance Phase assesses
the effect of incentives on treatment attendance and on post-treatment drug use, crime, and
psychosocial behaviors, including HIV risk behaviors. In addition, an incentive protocol
will test whether an incentive will encourage participation in HIV testing and counseling.
The intervention will last for six months.
Hypothesis 1. The use of incentives will significantly increase subject enrollment in
community treatment.
Hypothesis 2. The use of incentives will significantly increase subject retention in
community treatment.
Huypothesis 3. The use of incentives will significantly increase subject participation in
HIV testing and counseling.
Study participants will be interviewed at baseline and at 12 months following the
intervention. Treatment and criminal justice data will be obtained. Data on acceptability,
satisfaction, and sustainability will be collected from focus groups with staff and clients.
A considerable body of research indicates that prison-based treatment followed by continuing
treatment in the community is effective in reducing drug abuse and crime among drug-abusing
offenders. However, the impact of providing treatment is less than optimal because offenders
often fail to follow through on treatment referrals, leave treatment early, or have poor
engagement in treatment activities. In particular, participation in prison-based treatment
alone is seldom effective in reducing drug use or recidivism unless it is followed by
participation in community treatment. For correctional systems that provide a continuum of
care model from prison to community, low rates of admission and retention result in poor
outcomes and poor resource utilization. One way to address this problem is to provide
incentives to parolees for community treatment participation. Although research supports the
effectiveness of behavioral reinforcement, mainly in the form of contingency management
(CM), for general substance abuse populations, CM has not yet been tested or adapted for use
in community-based programs for offender populations, particularly to encourage treatment
attendance.
In addition, recent research has documented elevated rates of HIV infection among
incarcerated populations compared to the general population, with prevalence of HIV among
inmates in US prisons being estimated to be 6 to 10 times higher than in the general
population. Upon release from prison, parolees often immediately resume high-risk behaviors
that they engaged in prior to incarceration. Because of the high level of exposure to HIV
infection that accompanies drug use, particularly by injection, drug treatment programs for
high-risk offenders can serve as a valuable setting for preventing the spread of HIV, both
through HIV prevention/education activities and through access to HIV testing and
counseling.
Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse
Programs (ISAP), in collaboration with Walden House and the California Department of
Corrections and Rehabilitation, is conducting a five-year study that will involve a
randomized test of the use of incentives with parolees in a community-based residential
substance abuse treatment to increase treatment admission and treatment retention, and
thereby increase the likelihood of improved outcomes. Study participants will be recruited
from clients in a prison-based treatment program who have a referral to the Walden House
community program. The Admission Phase of the study assesses the effect of an incentive
(voucher) on enrolling in the Walden House program. The Attendance Phase assesses the effect
of incentives on treatment attendance and on post-treatment drug use, crime, and
psychosocial behaviors, including HIV risk behaviors. In addition, an incentive protocol
will test whether an incentive will encourage participation in HIV testing and counseling.
The intervention will last for six months.
Hypothesis 1. The use of incentives will significantly increase subject enrollment in
community treatment.
Hypothesis 2. The use of incentives will significantly increase subject retention in
community treatment.
Huypothesis 3. The use of incentives will significantly increase subject participation in
HIV testing and counseling.
Study participants will be interviewed at baseline and at 12 months following the
intervention. Treatment and criminal justice data will be obtained. Data on acceptability,
satisfaction, and sustainability will be collected from focus groups with staff and clients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |